ArticleCancer gene therapy2012
CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model.
Article in Cancer gene therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 35 citations in OpenAlex.
- Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.Journal of immunotherapy (Hagerstown, Md. : 1997) · 2013Trial
- Chemokine-chemokine receptor axis: Emerging immunotherapeutic paradigms for solid tumor microenvironment reprogramming.Chinese medical journal · 2026Review
- Preclinical evaluation of a CCL19 immune-potentiated DNA cancer vaccine.Cancer immunology, immunotherapy : CII · 2025Article
- DNA-based immunotherapy for cancer: In vivo approaches for recalcitrant targets.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Activated T cell therapy targeting glioblastoma cancer stem cells.Scientific reports · 2023Article
- Targeting neoantigens to APC-surface molecules improves the immunogenicity and anti-tumor efficacy of a DNA cancer vaccine.Frontiers in immunology · 2023Article
- Article
- HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.Archivum immunologiae et therapiae experimentalis · 2020Review
- CCL4 as an adjuvant for DNA vaccination in a Her2/neu mouse tumor model.Cancer gene therapy · 2016Article
- Clinical applications of mouse models for breast cancer engaging HER2/neu.Integrative cancer science and therapeutics · 2016Article
- Antibody response to HER2 extracellular domain and subdomains in mouse following DNA immunization.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- CCL21 and IFNγ recruit and activate tumor specific T cells in 3D scaffold model of breast cancer.Anti-cancer agents in medicinal chemistry · 2014Article
- The role of chemokines in breast cancer pathology and its possible use as therapeutic targets.Journal of immunology research · 2014Review
- Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma.Molecular cancer · 2013Article
- Chemokines as Cancer Vaccine Adjuvants.Vaccines · 2013Article
- Suppression of breast tumor growth by DNA vaccination against phosphatase of regenerating liver 3.Gene therapy · 2013Article
- Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity.PloS one · 2013Article
- Tailoring DNA Vaccines: Designing Strategies Against HER2-Positive Cancers.Frontiers in oncology · 2013Article
- HER2/neu DNA vaccination by intradermal gene delivery in a mouse tumor model: Gene gun is superior to jet injector in inducing CTL responses and protective immunity.Oncoimmunology · 2012Article
- CCL19 as an adjuvant for intradermal gene gun immunization in a Her2/neu mouse tumor model: improved vaccine efficacy and a role for B cells as APC.Cancer gene therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary lymphoid-tissue chemokine (SLC/CCL21) is a CC chemokine that is constitutively expressed in various lymphoid tissues and binds to chemokine receptor CCR7 on mature dendritic cells (DCs) and distinct T-and B-cell sub-populations. In vivo, CCL21 regulates the encounters between DC and T cells and thus is a key regulator of adaptive immune responses. We asked whether CCL21 is able to augment immunogenicity of a DNA-based vaccine against Her2/neu in a Balb/c mouse model with syngeneic Her2/neu+ tumor cells (D2F2/E2). Mice were vaccinated intramuscularly with plasmid DNA (pDNA) on day 1 and boosted on day 15; tumor challenge was performed subcutaneously on day 25. Coexpression of CCL21 and Her-2/neu resulted in induction of a TH1-polarized immune response and substantial improvement of the protective effect of the DNA vaccine. Coexpression of tumor antigen pDNA(Her2/neu) with both pDNA(GM-CSF) and pDNA(CCL21) as adjuvants led to further improvement of protection by the vaccine (70% tumor-free mice on day 35 vs 40% with either adjuvant alone vs 5-10% with tumor antigen alone). Our results show that CCL21 is a potent adjuvant for DNA vaccination, particularly in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF). Clinical use of a pDNA(Her2/neu/CCL21/GM-CSF) vaccine might be particularly promising in minimal residual Her2/neu+ breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.